U
AMRI

UBS’s Albany Molecular Research Inc AMRI Stock Holding History

UBS’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,645
Closed -$95.1K – 11071
2014
Q2 		$93K Buy
4,645
+1,645
+55% +$27.9K ﹤0.01% 6031
2014
Q1 		$56K Buy
3,000
+814
+37% +$11.2K ﹤0.01% 6690
2013
Q4 		$22K Buy
2,186
+1,686
+337% +$20.4K ﹤0.01% 8051
2013
Q3 		$6K Buy
+500
New +$6.15K ﹤0.01% 9321

Other funds holding AMRI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

UBS's AMRI Position: Q3 2014 in Review

UBS sold out of Albany Molecular Research Inc (AMRI) in Q3 2014, closing a stake of 4,645 shares — an estimated $95.1K sold.

UBS first reported a position in AMRI in Q3 2013 and held it in 4 quarters. The position peaked at $93K in Q2 2014. 143 funds tracked by Wall St. Rank hold AMRI as of Q3 2014.

  • UBS reported no remaining Albany Molecular Research Inc position as of Q3 2014 after selling out during the quarter.
  • UBS sold 4,645 Albany Molecular Research Inc shares in Q3 2014, an estimated $95.1K.
  • UBS first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 4 quarters.
  • UBS's Albany Molecular Research Inc position peaked at $93K in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.